Loading company…
Simcha Therapeutics Holding Company is a Connecticut clinical-stage immunobiology company developing cytokine therapies for cancer.
Founded in 2018, the company develops ST-067, an IL-18 cytokine that has shown potent antitumor effects in animal models, both alone and combined with anti-PD-1 checkpoint inhibitors. Its approach uses cytokine immunotherapies to stimulate the immune system against cancer. In January 2022 it raised USD 40 million in Series B funding led by SR One, with participation from ArrowMark Partners, BVF Partners, Logos Capital, Rock Springs Capital and Samsara BioCapital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in